← Thermo Fisher Scientific overview

Thermo Fisher Scientific vs Hitachi: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Thermo Fisher Scientific Inc (TMO)

Q3 2026
▲2▼1

Thermo Fisher Q3: Strong Q2 Results and New Wins, but China and Tariffs Weigh

  • Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating estimates. Management raised full-year guidance, and the stock jumped 8.7% to $572.32 as analysts lifted targets.

    This is the main positive force that drove the stock price during the quarter.

  • New Partnerships and Product Approvals Thermo Fisher announced an ImmuPharma manufacturing partnership, received FDA clearance for the EXENT myeloma test, and formed a Mayo Clinic venture called Precure. These expand its service offerings and add potential revenue streams.

    These new business wins support future growth and investor confidence.

  • Microbiology Sale Completed Thermo Fisher completed the $1.075 billion sale of its microbiology business. The deal frees up cash for other investments but trims near-term revenue, creating a mixed impact on the stock.

    This strategic move has both positive and negative implications for the company's financials.

  • China Weakness and Tariff Uncertainty China's academic and government demand remained weak, Asia-Pacific slightly missed expectations, and tariff uncertainty lingered. HSBC cut its target to $540, a real counterweight to the recovery.

    These risks put downward pressure on the stock and limit upside potential.

August 2026
▲3▼1

Thermo Fisher's recovery broadens, but China and tariffs weigh

  • FDA clears EXENT myeloma test The FDA cleared Thermo Fisher's EXENT myeloma test, a new product for diagnosing a type of blood cancer. This opens a fresh revenue stream and shows the company's testing business can grow beyond its current lineup.

    New product approval is a fresh positive driver for future sales.

  • Mayo Clinic Precure venture and new partnerships Thermo Fisher formed a venture with Mayo Clinic called Precure and announced other new products and partnerships. These deals broaden its future revenue sources and show its services remain in demand, supporting the stock.

    New collaborations expand future revenue and are new to this period.

  • Completed $1.075B microbiology sale Thermo Fisher completed the sale of its microbiology business for $1.075 billion. This frees up cash that can be used for other investments or debt reduction, but it also removes some near-term revenue, so the effect is mixed.

    Completing a major divestiture is a new event with mixed implications.

  • China weakness and tariff risks persist China's academic and government demand remains weak, Asia-Pacific missed slightly, and tariff risks continue. HSBC cut its target to $540, highlighting these as real counterweights to the recovery.

    These are ongoing risks that cap upside and are new details this period.

Latest
▲4

Thermo Fisher's recovery broadens as new products and deals build

  • Analysts raise targets after Q2 beat After Thermo Fisher's strong Q2, Simply Wall St lifted its fair value to $631 from $591, and Morgan Stanley, Barclays, BofA and Jefferies raised targets into the $630-650 range. Higher targets pull the stock up because they signal analysts expect more profit ahead. HSBC cut to $540, a real counterweight.

    Shows the market's upgraded view of TMO's value after results, a direct price driver.

  • Microbiology sale completed for $1.075 billion Thermo Fisher finished selling its microbiology business to Astorg for about $1.075 billion in cash plus a $50 million seller note. The unit had $645 million of 2025 revenue. Cash from the sale can fund buybacks or growth areas, but it also removes revenue near term, so the effect is mixed.

    A completed major transaction that changes TMO's business mix and cash position.

  • New products and partnerships widen offerings Thermo Fisher launched the EMPAD G2 electron detector, the Gibco CHO-K1 cell-culture panel, and agreed to resell Evosep's Eno proteomics platform. It also joined a Digital CMC Consortium and expanded cancer-monitoring work. These add future sales in instruments, bioprocessing and proteomics, supporting the stock.

    Product launches and deals are the main new growth drivers this period.

  • International revenue beats, China still a risk June-quarter revenue of $11.99 billion beat expectations, with Europe and other regions ahead of forecasts, though Asia-Pacific fell slightly short. Management said China returned to growth but academic and government demand there stayed weak, and tariff risks remain. Broad recovery supports the stock, but China is a real drag.

    Shows the geographic demand picture behind TMO's revenue beat and the key risk.

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

  • Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.

    This is the core new event that reset expectations for the company's earnings power.

  • Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.

    It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.

  • FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.

    A new regulatory approval expands the product portfolio and future revenue.

  • Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.

    A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 2026
▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

Q2 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

June 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

Hitachi, Ltd. (6501.JP)

Q3 2026
▲2▼2

Hitachi lifted by AI power demand, but risks temper outlook

  • AI data-center demand boosts profit forecast Hitachi raised its full-year net profit forecast 12.2% to ¥900bn, driven by strong demand for power equipment used in AI data centers. Q1 adjusted operating profit rose 39.5%.

    This is the main positive force behind Hitachi's performance in the quarter.

  • Digital and Energy units post strong profit growth Hitachi's Digital unit earned ¥450B at a 16.3% margin, while Energy profit jumped 65%. The company also expanded partnerships with OpenAI and Nvidia and invested $528M in a Mississippi transformer plant.

    These segment results and investments show the breadth of Hitachi's growth drivers.

  • Q1 net profit dipped slightly Despite the strong forecast, Hitachi's Q1 net profit fell slightly, showing that results can be uneven even as overall demand remains strong.

    This is a real counterweight that investors should note.

  • Long-term risks and regulatory pushback The US factory's payoff is years away (2029), nuclear projects are lumpy and permitting-sensitive, and face-recognition expansion faces privacy pushback that could slow adoption or trigger regulation.

    These risks could limit future growth and are important for a balanced view.

August 2026
▲3▼1

Hitachi rides AI power demand to record profits, expands capacity

  • Record profits from AI power and data-center demand Hitachi's Digital unit led earnings with ¥450B profit and 16.3% margin, while Energy profit jumped 65%, as AI data-center power demand drove record results.

    This is the core new financial performance showing how AI demand is boosting profits.

  • Expanding US transformer capacity and partnerships Hitachi is investing $528M in a Mississippi transformer plant and partnering with Mission Critical Group on data-center equipment, expanding its US footprint to meet AI infrastructure needs.

    This shows concrete new investments and partnerships to capture AI-driven demand.

  • New orders and services in rail, nuclear, and security Hitachi delivered Taiwan high-speed rail cars (¥124B order), secured a US nuclear construction permit with GE Vernova, and launched AI security and crypto-monitoring services, diversifying revenue.

    These new contracts and services show Hitachi's expansion into multiple growth areas.

  • Execution risks and regulatory pushback The US factory's payoff is years away (2029), nuclear projects are lumpy and permitting-sensitive, and face-recognition expansion faces privacy pushback that could slow adoption or trigger regulation.

    These are real counterweights that could temper the positive outlook.

Latest
▲3

Hitachi wins new orders and AI security deals, but privacy and project risks linger

  • Taiwan high-speed rail order delivers Hitachi's consortium shipped the first N700ST train cars to Taiwan for a 12-set order worth about 124 billion yen. This confirms delivery on a major contract, supporting future revenue and showing Hitachi's rail business can win and execute large overseas deals.

    This is a concrete new order delivery that supports Hitachi's revenue outlook and shows execution on a major contract.

  • US nuclear reactor permit secured GE Vernova and Hitachi won a US construction permit for a new reactor design. This opens the door to licensed nuclear construction, adding long-term, high-value projects. But nuclear work is lumpy and sensitive to permitting delays, so the payoff is years away.

    This is a new regulatory win that expands Hitachi's nuclear business and adds long-term revenue potential.

  • New AI security and crypto monitoring services Hitachi launched a crypto money-laundering monitoring service and joined Anthropic's critical infrastructure cybersecurity program. These moves expand its digital and AI offerings into fast-growing security markets, supporting future service revenue and keeping Hitachi tied to leading AI platforms.

    These are new service launches that show Hitachi expanding into high-growth AI and security markets.

  • Face recognition expansion meets privacy concerns Hitachi's face recognition gates expanded to more stations and commercial uses, showing growing adoption. But privacy advocates warn about tracking and misuse, which could slow adoption or invite regulation. The technology is promising but faces real social and legal pushback.

    This shows both the growth potential and the regulatory/privacy risks of Hitachi's biometric business.

▲4

Hitachi rides AI power and data-center demand with record profits and US expansion

  • Nvidia physical AI coalition Hitachi joined Nvidia's physical AI coalition, building robots and industrial AI on Nvidia's platforms. This ties Hitachi to Japan's huge government-backed AI robotics push, a long-term source of orders for its digital and industrial businesses, supporting the shares.

    New partnership signals durable AI-driven demand for Hitachi.

  • Digital unit leads profit Full-year results show Hitachi's Digital Systems & Services unit earned 450 billion yen, the most of any segment, with a 16.3% margin, while Energy profit jumped 65%. Strong, higher-margin earnings underpin the stock and justify its recovery toward the 5,400 yen range.

    Earnings power is the core fundamental driver of the share price.

  • US transformer factory Hitachi Energy will spend $528 million (about 82 billion yen) on a Mississippi transformer plant, part of a $1.5 billion US expansion, to meet AI-driven electricity demand. It adds long-term capacity and revenue, though the cash outlay and 2029 start mean payoff is years away.

    Major capex shows Hitachi positioning for AI power demand.

  • Data-center partnership Hitachi signed an MoU with Mission Critical Group to jointly build and sell data-center power and modular equipment, combining Hitachi Energy and digital tech with MCG's 18 US factories. It widens Hitachi's reach into a market growing about 20% a year, supporting future orders.

    New partnership expands Hitachi's data-center addressable market.

July 2026
▲3▼1

Hitachi lifts profit outlook on AI demand, expands tech partnerships

  • AI partnerships and recognition Hitachi expanded its OpenAI partnership for banking and cybersecurity, earned WEF recognition for its Oklahoma plant, and joined Nvidia's physical AI coalition, strengthening its AI credentials.

    These moves highlight Hitachi's growing AI ecosystem and potential for future revenue.

  • Raised profit forecast on AI data-center power demand Hitachi raised its full-year net profit forecast by 12.2% to ¥900bn, driven by AI data-center power demand, and reported Q1 adjusted operating profit up 39.5%.

    This directly reflects improved financial performance and outlook, a key driver for the stock.

  • New services and market expansion Hitachi announced a new crypto AML service and saw expanded rail battery demand, indicating diversification into new areas and additional revenue streams.

    These initiatives show Hitachi's efforts to broaden its business beyond core segments.

  • Q1 net profit dip and execution risks Despite overall strength, Q1 net profit declined slightly, and reliance on AI-driven demand plus execution challenges in new partnerships and markets temper the positive outlook.

    This provides a balanced view by highlighting potential headwinds that could affect future performance.

▲4

Hitachi lifts profit outlook on AI data-center power demand

  • Hitachi raises full-year profit forecast on AI data-center power demand Hitachi lifted its full-year net profit forecast to 900 billion yen, up 12.2%, and adjusted operating profit to 1.408 trillion yen. The upgrade is driven by strong sales of power transmission equipment used in AI data centers, showing its energy business is a real growth engine.

    This is the main new event that directly answers why the stock is moving now.

  • Q1 profit dips slightly but core operating profit jumps 39.5% First-quarter net profit slipped 1.4% to 189.45 billion yen, but adjusted operating profit surged 39.5% to 294.2 billion yen and revenue rose to 2.71 trillion yen. The profit dip is minor; the strong underlying operating performance supports the upbeat outlook.

    It shows the earnings quality behind the raised forecast, which investors care about.

  • New anti-money laundering service for crypto assets Hitachi will launch an AML monitoring service in October for crypto, stablecoins, and NFTs, after a proof-of-concept with 17 financial and crypto firms. This opens a new revenue stream in digital-asset compliance, a fast-growing area, and shows Hitachi's ability to turn regulation into business.

    It is a new product launch that adds a future growth driver beyond the current earnings story.

  • Rail battery expansion signals strong train orders Turntide is expanding battery production because of demand from Hitachi Rail, supporting hybrid trains built in the UK. This points to a healthy order book in Hitachi's rail business, adding to confidence in its industrial segment.

    It is a fresh demand signal for Hitachi's rail unit, which is part of the overall growth picture.

▲4

Hitachi deepens AI ties with OpenAI and Nvidia, turning AI into real products

  • OpenAI partnership expands into legacy systems and cybersecurity Hitachi is widening its OpenAI work: joint engineer teams will use OpenAI's Codex AI to read and modernize old bank computer systems, and Hitachi gets OpenAI cyber models to defend against attacks. This makes Hitachi's AI services more valuable and opens a new market, supporting the share price.

    A concrete new partnership that expands Hitachi's AI business and revenue opportunity.

  • Oklahoma factory wins WEF Global Lighthouse recognition Hitachi Vantara's Oklahoma storage plant was named a World Economic Forum Lighthouse factory after AI cut order-to-shipment time 77% and inventory 50%. Hitachi will fold these proven AI methods into its HMAX product suite, showing customers real results and strengthening its AI-selling story.

    New proof point that Hitachi's own AI works, boosting credibility and future sales.

  • Hitachi joins Nvidia's physical AI push in Japan At Nvidia's Tokyo event, Hitachi said it will join the Cosmos Coalition for open physical AI models and work with Nvidia to integrate and control whole sites like factories and power plants. This positions Hitachi in the fast-growing robot-and-factory AI market, a positive for future orders.

    New Nvidia partnership directly ties Hitachi to the physical AI theme investors are watching.

  • Intel foundry interest and Hitachi physical AI tie reinforce chip supply Reports say Google and Nvidia may use Intel's chip factories as capacity runs short, and Intel and Hitachi already announced a June collaboration on physical AI and next-generation computing. Stronger Intel foundry prospects support the hardware side of Hitachi's AI and infrastructure plans.

    Links Hitachi's earlier Intel tie to a broader chip-supply story that underpins its AI hardware.